International Journal of Medical and Dental Sciences

The PDF file you selected should load here if your Web browser has a PDF reader plug-in installed (for example, a recent version of Adobe Acrobat Reader).

If you would like more information about how to print, save, and work with PDFs, Highwire Press provides a helpful Frequently Asked Questions about PDFs.

Alternatively, you can download the PDF file directly to your computer, from where it can be opened using a PDF reader. To download the PDF, click the Download link above.

Fullscreen Fullscreen Off


Rheumatoid arthritis is a debilitating disease that has significant impact on quality of life. Biological and non biological DMARDs improved the outcome in RA patients. New agents are still required in inadequate responders or intolerant patients. FDA has recently approved a new drug Sarilumab, a monoclonal antibody for the treatment of moderate to severe form of RA which acts by binding to Interleukin receptor 6 and interrupts the resultant cytokine-mediated inflammatory signaling.

Keywords

IL-6, Monoclonal Antibody, Sarilumab, Cytokine.
User
Notifications
Font Size